KRAS Inhibitors Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on KRAS Inhibitors Market 

5.1. COVID-19 Landscape: KRAS Inhibitors Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global KRAS Inhibitors Market, By Cancer Type

8.1. KRAS Inhibitors Market Revenue and Volume, by Cancer Type, 2024-2034

8.1.1. Lung Cancer

8.1.1.1. Market Revenue and Volume Forecast (2021-2034)

8.1.2. Pancreatic Cancer

8.1.2.1. Market Revenue and Volume Forecast (2021-2034)

8.1.3. Colorectal Cancer

8.1.3.1. Market Revenue and Volume Forecast (2021-2034)

8.1.4. Others

8.1.4.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 9. Global KRAS Inhibitors Market, By End-Use

9.1. KRAS Inhibitors Market Revenue and Volume, by End-Use, 2024-2034

9.1.1. Clinic Laboratories

9.1.1.1. Market Revenue and Volume Forecast (2021-2034)

9.1.2. Cancer Diagnostic Centers

9.1.2.1. Market Revenue and Volume Forecast (2021-2034)

9.1.3. Hospitals

9.1.3.1. Market Revenue and Volume Forecast (2021-2034)

9.1.4. Cancer Research Institutes

9.1.4.1. Market Revenue and Volume Forecast (2021-2034)

9.1.5. Academic Institutions

9.1.5.1. Market Revenue and Volume Forecast (2021-2034)

9.1.6. Others

9.1.6.1. Market Revenue and Volume Forecast (2021-2034)

Chapter 10. Global KRAS Inhibitors Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.1.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.1.3. U.S.

10.1.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.1.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.1.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.2. Europe

10.2.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.2.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.2.3. UK

10.2.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.2.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.2.4. Germany

10.2.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.2.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.2.5. France

10.2.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.2.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.2.6.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.3. APAC

10.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.3.3. India

10.3.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.3.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.3.4. China

10.3.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.3.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.3.5. Japan

10.3.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.3.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.3.6.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.4. MEA

10.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.4.3. GCC

10.4.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.4.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.4.4. North Africa

10.4.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.4.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.4.5. South Africa

10.4.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.4.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.4.6.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.5. Latin America

10.5.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.5.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.5.3. Brazil

10.5.3.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.5.3.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Volume Forecast, by Cancer Type (2021-2034)

10.5.4.2. Market Revenue and Volume Forecast, by End-Use (2021-2034)

Chapter 11. Company Profiles

11.1. Amgen

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Boehringer Ingelheim

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. BridgeBio Pharma

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Erasca

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. Innovent Biologics, Inc.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. Incyte

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. Mirati Therapeutics

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Novartis

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Jemincare

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Cardiff Oncology, Inc.

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms